Management of malignant pleural effusions

Respirology

Volumn 9, Issue 2, 2004, Pages 148-156

  Lee, Y C Gary ^a,b,c   Light, Richard W ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SAINT THOMAS HOSPITAL   (United States)

Author keywords

Malignant; Pleural effusion; Pleurodesis

Indexed keywords

BLEOMYCIN; CORTICOSTEROID; DOXYCYCLINE; HEPARIN; INTERLEUKIN 8; NARCOTIC ANALGESIC AGENT; OXYGEN; TALC; TETRACYCLINE; TRANSFORMING GROWTH FACTOR BETA;

ADULT RESPIRATORY DISTRESS SYNDROME; AMBULATORY SURGERY; CATHETERIZATION; CLINICAL PRACTICE; DISEASE ASSOCIATION; FUTUROLOGY; HOSPITAL PATIENT; HUMAN; PAIN; PLEURA EFFUSION; PLEURA FLUID; PLEURODESIS; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT;

HUMANS; PATIENT SELECTION; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; RECURRENCE; TALC;

EID: 3042558752     PISSN: 13237799     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2004.00566.x     Document Type: Review

References (96)

1. Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest 1993; 104: 1486-9.
2. Marel M, Stastny B, Melinova L, Svandova E, Light RW. Diagnosis of pleural effusions. Experience with clinical studies, 1986-90. Chest 1995; 107: 1598-603.
3. Bouros D, Froudarakis M, Siafakas NM. Pleurodesis: everything flows. Chest 2000; 118: 577-9.
4. Sahn SA. Pleural diseases related to metastatic malignancies. Eur. Respir. J. 1997; 10: 1907-13.
5. Lee YCG, Baumann MH, Maskell NA et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. Chest 2003; 124: 2229-38.
6. Sahn SA. Malignancy metastatic to the pleura. Clin. Chest Med. 1998; 19: 351-61.
7. Ang P, Tan EH, Leong SS et al. Primary intrathoracic malignant effusion: a descriptive study. Chest 2001; 120: 50-4.
8. Lee YCG, De Klerk NH, Henderson DW, Musk AW. Malignant mesothelioma. In: Hendrick DJ, Burge PS, Beckett WS, Churg A (eds). Occupational Disorder of the Lung. Recognition, Management and Prevention. WB Saunders, London, 2002; 359-79.
9. Lee YCG, Dean A, Thompson RI, Robinson BWS, Robinson BWS, Chahinian P (eds). Mesothelioma. Martin Dunitz, London, 2002; 111-26.
10. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma, a prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer 1993; 72: 389-93.
11. Grove CS, Lee YCG. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr. Opin. Pulm. Med. 2002; 8: 294-301.
12. Yano S, Shinohara H, Herbst RS et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am. J. Pathol. 2000; 157: 1893-903.
13. Yano S, Herbst RS, Shinohara H et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin. Cancer Res. 2000; 6: 957-65.
14. Light RW, Lee YCG. Textbook of Pleural Diseases. Arnold Press, London, 2003.
15. Light RW. Clinical practice. Pleural effusion. N. Engl. J. Med. 2002; 346: 1971-7.
16. Lee YCG, Davies RJO. Management of pleural effusions in acute medical settings: a practical guide. CPDJ. Acute Med. 2004; 3: 26-32.
17. Sallach SM, Sallach JA, Vasquez E, Schultz L, Kvale P. Volume of pleural fluid required for diagnosis of pleural malignancy. Chest 2002; 122: 1913-17.
18. Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin. Proc. 1985; 60: 158-64.
19. Gorg C, Restrepo I, Schwerk WB. Sonography of malignant pleural effusion. Eur. Radiol. 1997; 7: 1195-8.
20. Adams RF, Gleeson FV. Percutaneous image-guided cutting-needle biopsy of the pleura in the presence of a suspected malignant effusion. Radiology 2001; 219: 510-4.
21. Maskell NA, Gleeson FV, Davies RJO. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis malignant disease in pleural effusions: a randomised controlled trial. Lancet 2003; 361: 1326-30.
22. Wang ZJ, Reddy GP, Gotway MB et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 2004; 24: 105-19.
23. Loddenkemper R. Medical thoracoscopy. In: Light RW, Lee YCG (eds). Textbook of Pleural Diseases. Arnold Press, London, 2003; 498-512.
24. Loddenkemper R, Schonfeld N. Medical thoracoscopy. Curr. Opin. Pulm. Med. 1998; 4: 235-8.
25. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. Chest2000; 117: 87-95.
26. Loddenkemper R. Are prognostic factors helpful in determining the indication for pleurodesis in malignant pleural effusions? Respiration 1998; 65: 106-7.
27. Light RW. Pleural Diseases. Lippincott Williams & Wilkins, Baltimore, 2001.
28. Lee YCG, Rodriguez RM, Lane KB, Light RW. Pleurodesis for recurrent pleural effusions in the new millennium. Recent Adv. Res. Updates 2001; 2: 81-9.
29. Shinto RA, Stansbury DW, Fischer CE, Light RW. Does therapeutic thoracentesis improve the exercise capacity of patients with pleural effusion? Am. Rev. Respir. Dis. 1988; 135: A244.
30. Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions. An assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000; 117: 73-8.
31. Martinez-Moragon E, Aparicio J, Sanchis J, Menendez R, Cruz Rogado M, Sanchis F. Malignant pleural effusion. prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998; 65: 108-13.
32. Bernard A, de Dompsure RB, Hagry O, Favre IP. Early and late mortality after pleurodesis for malignant pleural effusion. Ann. Thorac. Surg. 2002; 74: 213-17.
33. Rodriguez Panadero F. Malignant pleural effusions. In: Light RW, Lee YCG (eds). Textbook of Pleural Diseases. Arnold Press, London, 2003; 297-309.
34. Yim AP, Chan AT, Lee TW, Wan IY, Ho JK. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann. Thorac. Surg. 1996; 62: 1655-8.
35. Colt HG. Thoracoscopic management of malignant pleural effusions. Clin. Chest Med. 1995; 16: 505-18.
36. Martini N, Bains MS, Beattie EJ Jr. Indications for pleurectomy in malignant effusion. Cancer 1975; 35: 734-8.
37. Fry WA, Khandekar JD. Parietal pleurectomy for malignant pleural effusion. Ann. Surg. Oncol. 1995; 2: 160-4.
38. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann. Intern. Med. 1994; 120: 56-64.
39. Hartman DL, Gaither JM, Kesler KA, Mylet DM, Brown JW, Mathur PN. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J. Thorac. Cardiovasc. Surg. 1993; 105: 743-8.
40. Noppen M, Degreve J, Mignolet M, Vincken W. A prospective, randomised study comparing the efficacy of talc slurry and bleomycin in the treatment of malignant pleural effusions. Acta Clin. Belg. 1997; 52: 258-62.
41. Webb WR, Ozmen V, Moulder PV, Shabahang B, Breaux J. Iodized talc pleurodesis for the treatment of pleural effusions. J. Thorac. Cardiovasc. Surg. 1992; 103: 881-6.
42. Kennedy L, Rusch VW, Strange C, Ginsberg RJ, Sahn SA. Pleurodesis using talc slurry. Chest 1994; 106: 342-6.
43. Adler RH, Sayek I. Treatment of malignant pleural effusion: a method using tube thoracostomy and talc. Ann. Thorac. Surg. 1976; 22: 8-15.
44. Hamed H, Fentiman IS, Chaudary MA, Rubens RD. Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast. Br. J. Surg. 1989; 76: 1266-7.
45. Fentiman IS, Rubens RD, Hayward JL. Control of pleural effusions in patients with breast cancer. A randomized trial. Cancer 1983; 52: 737-9.
46. Fentiman IS, Rubens RD, Hayward JL. A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer. Eur. J. Cancer Clin. Oncol. 1986; 22: 1079-81.
47. Olivares-Torres CA, Laniado-Laborin R, Chavez-Garcia C, Leon-Gastelum C, Reyes-Escamilla A, Light RW. Iodopovidone pleurodesis for recurrent pleural effusions. Chest2002; 122: 581-3.
48. Marchi E, Teixeira LR, Vargas FS. Management of malignancy-associated pleural effusion: current and future treatment strategies. Am. J. Respir. Med. 2003; 2: 261-73.
49. Lee YCG, Lane KB. The many faces of transforming growth factor-beta in pleural diseases. Curr. Opin. Pulm. Med. 2001; 7: 173-9.
50. van den Heuvel MM, Smit HJ, Barbierato SB, Havenith CE, Beelen RH, Postmus PE. Talc-induced inflammation in the pleural cavity. Eur. Respir. J. 1998; 12: 1419-23.
51. Rinaldo JE, Owens GR, Rogers RM. Adult respiratory distress syndrome following intrapleural instillation of talc. J. Thorac. Cardiovasc. Surg. 1983; 85: 523-6.
52. Bouchama A, Chastre J, Gaudichet A, Soler P, Gibert C. Acute pneumonitis with bilateral pleural effusion after talc pleurodesis. Chest 1984; 86: 793-7.
53. Marel M, Skacel Z, Bednar M, Julak J, Light RW. Corynebacterium parvum, bleomycin and talc in the treatment of malignant pleural effusions. J. Buon. 1998; 1: 165-70.
54. Rehse DH, Aye RW, Florence MG. Respiratory failure following talc pleurodesis. Am. J. Surg. 1999; 177: 437-40.
55. Todd TR, Delarue NC, Ilves R, Pearson FG, Cooper JD. Talc poudrage for malignant pleural effusion. Chest 1980; 78: 542-3.
56. Nandi P. Recurrent spontaneous pneumothorax; an effective method of talc poudrage. Chest 1980; 77: 493-5.
57. Migueres J, Jover A. Indications for intrapleural talc under pleuroscopic control in malignant recurrent pleural effusions. Based on 26 cases. Poumon. Coeur. 1981; 37: 295-7 (in French).
58. Campos JR, Werebe EC, Vargas FS, Jatene FB, Light RW. Respiratory failure due to insufflated talc. Lancet 1997; 349: 251-2.
59. Light RW. Talc should not be used for pleurodesis. Am. J. Respir. Crit. Care Med. 2000; 162: 2024-6.
60. Ferrer J, Montes JF, Villarino MA, Light RW, Garcia-Valero J. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest 2002; 122: 1018-27.
61. Ferrer J, Villarino MA, Tura JM, Traveria A, Light RW. Talc preparations used for pleurodesis vary markedly from one preparation to another. Chest 2001; 119: 1901-5.
62. Maskell NA, Lee YCG, Gleeson FV, Jones E, Pengelly G, Davies RIO. Prospective randomized trials comparing the influence of talc of different particle sizes and tetra-cycline on lung and systemic inflammation after pleurodesis. Am. J. Respir. Crit. Care Med. 2004; in press.
63. Light RW. Talc for pleurodesis? Chest 2002; 122: 1506-8.
64. Sahn SA. Talc should be used for pleurodesis. Am. J. Respir. Crit. Care Med. 2000; 162: 2023-4.
65. Seaton KG, Patz EF Jr, Goodman PC. Palliative treatment of malignant pleural effusions: value of small-bore catheter thoracostomy and doxycycline sclerotherapy. AJR Am. J. Roentgenol. 1995; 164: 589-91.
66. Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions. Ann. Thorac. Surg. 1993; 55: 1115-21.
67. Heffner JE, Standerfer RJ, Torstveit J, Unruh L. Clinical efficacy of doxycycline for pleurodesis. Chest 1994; 105: 1743-7.
68. Mansson T. Treatment of malignant pleural effusion with doxycycline. Scand. J. Infect. Dis. Suppl. 1988; 53: 29-34.
69. Diacon AH, Wyser C, Bollinger CT et al. Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am. J. Respir. Crit. Care Med. 2000; 162: 1445-9.
70. Vargas FS, Wang NS, Lee HM, Gruer SE, Sassoon CS, Light RW. Effectiveness of bleomycin in comparison to tetracycline as pleural sclerosing agent in rabbits. Chest 1993; 104: 1582-4.
71. Putnam JB Jr, Light RW, Rodriguez RM et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999; 86: 1992-9.
72. Putnam JB Jr, Walsh GL, Swisher SG et al. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann. Thorac. Surg. 2000; 69: 369-75.
73. Clementsen P, Evald T, Grode G, Hansen M, Krag Jacobsen G, Faurschou P. Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. A prospective randomized study. Respir. Med. 1998; 92: 593-6.
74. Morrison MC, Mueller PR, Lee MJ et al. Sclerotherapy of malignant pleural effusion through sonographically placed small-bore catheters. AJR Am. J. Roentgenol. 1992; 158: 41-3.
75. Patz EF Jr, McAdams HP, Erasmus JJ et al. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest 1998; 113: 1305-11.
76. Patz EF Jr, McAdams HP, Goodman PC, Blackwell S, Crawford J. Ambulatory sclerotherapy for malignant pleural effusions. Radiology 1996; 199: 133-5.
77. Robinson RD, Fullerton DA, Albert JD, Sorensen J, Johnston MR. Use of pleural Tenckhoff catheter to palliate malignant pleural effusion. Ann. Thorac. Surg. 1994; 57: 286-8.
78. Goff BA, Mueller PR, Muntz HG, Rice LW. Small chest-tube drainage followed by bleomycin sclerosis for malignant pleural effusions. Obstet. Gynecol. 1993; 81: 993-6.
79. Villanueva AG, Gray AW Jr, Shahian DM, Williamson WA, Beamis JF Jr. Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax 1994; 49: 23-5.
80. Antunes G, Neville E, Duffy J, Ali N. BTS guidelines for the management of malignant pleural effusions. Thorax 2003; 58 (Suppl. 2): ii29-38.
81. Dryzer SR, Allen ML, Strange C, Sahn SA. A comparison of rotation and non-rotation in tetracycline pleurodesis. Chest 1993; 104: 1763-6.
82. Mager HJ, Maesen B, Verzijlbergen F, Schramel F. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung Cancer 2002; 36: 77-81.
83. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108: 754-8.
84. Xie C, Teixeira LR, McGovern JP, Light RW. Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am. J. Respir. Crit. Care Med. 1998; 157: 1441-4.
85. Teixeira LR, Wu W, Chang DS, Light RW. The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits. Chest2002; 121: 216-9.
86. Idell S. Pleural fibrosis. In: Light RW, LeeYCG (eds). Textbook of Pleural Diseases. Arnold Press, London, 2003; 96-108.
87. Rodriguez-Panadero F, Segado A, Martin Juan J, Ayerbe R, Torres Garcia I, Castillo J. Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am. J. Respir. Crit. Care Med. 1995; 151: 785-90.
88. Strange C, Baumann MH, Sahn SA, Idell S. Effects of intrapleural heparin or urokinase on the extent of tetra-cycline-induced pleural disease. Am. J. Respir. Crit. Care Med. 1995; 151: 508-15.
89. Marom EM, Patz EF Jr, Erasmus JJ, McAdams HP, Goodman PC, Herndon JE. Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis. Radiology 1999; 210: 277-81.
90. Petrou M, Kaplan D, Goldstraw P. Management of recurrent malignant pleural effusions. The complementary role of talc pleurodesis and pleuroperitoneal shunting. Cancer 1995; 75: 801-5.
91. Herrstedt J, Clementsen P, Hansen OP. Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer. Eur. J. Cancer 1992; 28A: 1070-3.
92. Lee YCG, Light RW. Future directions. In: Light RW, Lee YCG (eds). Textbook of Pleural Diseases. Arnold Press, London, 2003; 536-41.
93. Lee YCG, Teixeira LR, Devin CJ et al. Transforming growth factor-β2 induces pleurodesis significantly faster than talc. Am. J. Respir. Crit. Care Med. 2001; 163: 640-4.
94. Lee YCG, Yasay JR, Johnson JE et al. Comparing transforming growth factor-β2, talc and bleomycin as pleurodesing agents in sheep. Respirology 2002; 7: 209-16.
95. Lee YCG, Lane KB, Zoia O, Thompson PJ, Light RW, Blackwell TS. Transforming growth factor-beta induces collagen synthesis without inducing IL-8 production in mesothelial cells. Eur. Respir. J. 2003; 22: 197-202.
96. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21: 2636-44.